Clinical Trials
12
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 3:5
Not Applicable:3
Drug Approvals
2
PHILIPPINES:2
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (55.6%)Not Applicable
3 (33.3%)Phase 1
1 (11.1%)A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)
Not Applicable
Not yet recruiting
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Dimethyl Fumarate Enteric-coated Capsules
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07138833
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Phase 3
Completed
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 518
- Registration Number
- NCT06932107
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China
A Study of QLM2011 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 172
- Registration Number
- NCT06925659
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT06446310
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Jieyang People's Hospital, Jieyang, Guangdong, China
🇨🇳Shandong Provincial Hospital, Jinan, Shandong, China
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 378
- Registration Number
- NCT05922436
- Prev
- 1
- 2
- Next
News
No news found